Thubrikar Aortic Valve, Inc. (the “Company”) is a privately-held medical device company founded in October 2010 by Dr. Mano Thubrikar to develop and test a next-generation Transcatheter Aortic Valve Implantation (TAVI) device – Optimum TAV – and its catheter-delivery system, both of which were developed using his 30+ years of research on the aortic valve and bioprostheses.

Since its founding, the Company has raised over $3.5 Million in 3 rounds of financing from Wide Line, founders, friends and family, physicians, entrepreneurs and executives from the lifesciences and other technology industries, the Delaware Crossing Investor Group, Heartland Angels (Chicago), Lehigh Valley Angel Investors, and other Angel Group members.

The Company has completed nearly all pre-clinical tests, which includes surpassing the ISO/FDA-compliant durability test in under $1 Million.

The Company is headquartered near Philadelphia, Pennsylvania U.S.A.